{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"70","upperLimit":"84","value":"78.1"},{"groupId":"OG001","lowerLimit":"72","upperLimit":"85","value":"79.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"224"}],"units":"Participants"}],"description":"Estimate for probability of overall survival at 3 years by Kaplan-Meier method, where overall survival is defined as the time from randomization to time of death due to any cause or the date of last contact, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive cisplatin IV over 90 minutes on days 2, 9, 16, 23, 30, (and day 36 or 37 at the treating physician's discretion). Patients then undergo EBRT (either conventional RT or IMRT) QD 5 days a week for 25 fractions followed by LDR or HDR brachytherapy according to institution's standards. Treatment continues in the absence of disease progression or unacceptable toxicity.\n\nBrachytherapy: Undergo brachytherapy\n\nCisplatin: Given IV\n\nExternal Beam Radiation Therapy: Undergo EBRT\n\nIntensity-Modulated Radiation Therapy: Undergo IMRT\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRadiation Therapy: Undergo conventional RT","id":"OG000","title":"Arm I (Cisplatin, IMRT or RT, Brachytherapy)"},{"description":"Patients receive cisplatin and undergo EBRT followed by brachytherapy as in Arm I. Patients also receive triapine IV over 2 hours on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33. Treatment continues in the absence of disease progression or unacceptable toxicity.\n\nBrachytherapy: Undergo brachytherapy\n\nCisplatin: Given IV\n\nIntensity-Modulated Radiation Therapy: Undergo IMRT\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRadiation Therapy: Undergo conventional RT\n\nTriapine: Given IV","id":"OG001","title":"Arm II (Cisplatin, IMRT or RT, Brachytherapy, Triapine)"}],"paramType":"NUMBER","populationDescription":"Eligible participants","reportingStatus":"POSTED","timeFrame":"At 3 years from randomization.","title":"Overall Survival (OS) Rate at 3 Years","type":"PRIMARY","unitOfMeasure":"percentage of participants"}